Author

N. Tatari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Buck· 2 shared A. Khoo· 2 shared B. Snijder· 2 shared C. Chokshi· 2 shared C. Venugopal· 2 shared D. Bakhshinyan· 2 shared D. Kaymak· 2 shared G. Hutter· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Buck

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

T. A. Martins, N. Tatari, D. Kaymak, S. Hogan, E. M. Bartoszek, R. Wieboldt, M.-F. Ritz, A. Buck, M. McDaid, A. Gerber, A. Beshirova, M. M. Etter, A. Heider, T. Shekarian, H. Mohamed, , G. Hutter

This paper develops a CAR T cell therapy that secretes a CD47 blocker to enhance anti-EGFRvIII efficacy against glioblastoma by modulating the tumor microenvironment.

bioRxiv · Aug 31, 2023Cancer Biology

The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma

P. Schmassmann, J. Roux, A. Buck, N. Tatari, S. Hogan, J. Wang, S. Lee, B. Snijder, T. A. Martins, M.-F. Ritz, T. Shekarian, D. Kaymak, M. McDaid, M. Weller, T. Weiss, , G. Hutter

This study identifies the Siglec-sialic acid-axis as a target for innate immunotherapy in glioblastoma, showing that blocking Siglec-E enhances phagocytosis and T cell priming, leading to delayed tumor growth and prolonged survival.

bioRxiv · Nov 7, 2022Cancer Biology

Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma

M. A. Qazi, S. K. Salim, K. R. Brown, N. Mikolajewicz, N. Savage, H. Han, M. K. Subapanditha, D. Bakhshinyan, A. Nixon, P. Vora, K. Desmond, C. Chokshi, M. Singh, A. Khoo, A. Macklin, , S. K. Singh

This study characterizes the minimal residual disease state in glioblastoma, revealing distinct evolutionary trajectories and immunomodulatory signatures associated with recurrence.

bioRxiv · Jan 28, 2022Cancer Biology

Hitting more birds with one stone: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma

M. Seyfrid, W. Maich, V. M. Shaikh, N. Tatari, D. Upreti, D. Piyasena, M. Subapanditha, N. Savage, D. McKenna, L. Kuhlmann, A. Khoo, S. K. Salim, B. Bassey-Archibong, W. D. Gwynne, C. Chokshi, , S. K. Singh

This study identifies CD70 as a therapeutic target for recurrent glioblastoma, showing that CD70 knockdown reduces tumorigenicity and CD70 CAR-T therapy improves survival in animal models.

bioRxiv · Jun 2, 2021 · PreprintCancer Biology